Trial Profile
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Ofatumumab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 12 Sep 2023 Status changed from active, no longer recruiting to completed.
- 01 Dec 2022 Results assessing the efficacy of Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma published in the Leukemia and Lymphoma
- 03 Oct 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.